Glanzmann's thrombasthenia associated with gastrointestinal angiodysplasias successfully treated with bevacizumab

Blood Coagul Fibrinolysis. 2023 Dec 1;34(8):545-548. doi: 10.1097/MBC.0000000000001249. Epub 2023 Oct 20.

Abstract

Glanzmann's Thrombasthenia (GT) is a rare hemorrhagic condition caused by a platelet surface receptor disorder of the glycoprotein (GP) IIb/IIIa. Symptoms of GT are various forms of hemorrhages, such as purpura, epistaxis and menorrhagia. Gastrointestinal bleeding (GIB) is a rare expression of the condition and may occur due to traumas in the GI tract or as a consequence of gastrointestinal angiodysplasia (GIADs). In this case report, we present a middle-aged woman with recurrent GIB consequent to GIADs with persistent melena and iron deficiency anemia. After several unsuccessful therapeutic interventions, the patient was studied by the hereditary hemorrhagic telangiectasia's (HHT - Osler-Weber-Rendu disease) unit, where she received bevacizumab, showing a complete improvement in symptoms as well as a reduction in her GIADs. This case shows that bevacizumab could be a possible line of treatment for patients with coagulation disorders with GIADs.

Publication types

  • Case Reports

MeSH terms

  • Angiodysplasia* / complications
  • Angiodysplasia* / drug therapy
  • Bevacizumab / therapeutic use
  • Blood Platelet Disorders*
  • Female
  • Gastrointestinal Hemorrhage / complications
  • Gastrointestinal Hemorrhage / etiology
  • Humans
  • Menorrhagia* / etiology
  • Middle Aged
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Rare Diseases / complications
  • Thrombasthenia* / complications
  • Thrombasthenia* / drug therapy

Substances

  • Bevacizumab
  • Platelet Glycoprotein GPIIb-IIIa Complex